Karen Vigil, MD
Infectious Disease · Houston, TXNPI 1760795017
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 64.1% of it on its own, with 13 other manufacturers making up the rest. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $509.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$58K
- Viiv Healthcare Company$24K
- Janssen Products, LP$4K
- Theratechnologies Inc.$3K
- Astellas Pharma US Inc$318
- Merck$292
- plus $554 from 8 others
Across 36 payments — averaging $35,344 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Theratechnologies Inc.$1.1M
- Viiv Healthcare Company$86K
- Merck$38K
What the payments were for
- Consulting fees$42,30546%
- Speaking & faculty fees$34,36138%
- Travel & lodging$10,41311%
- Food & beverage$3,5254%
- Education$5161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 70 | $58,416 |
| Viiv Healthcare Company | 47 | $23,635 |
| Janssen Products, LP | 7 | $4,492 |
| Theratechnologies Inc. | 6 | $3,412 |
| Astellas Pharma US Inc | 5 | $318 |
| Merck | 17 | $292 |
| Melinta Therapeutics, LLC | 16 | $290 |
| Comsort, Inc | 1 | $100 |
| Paratek Pharmaceuticals, Inc. | 3 | $62 |
| Pfizer | 3 | $43 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| EMD Serono, Inc. | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$91,119 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 748 | $2,937,284 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 66 | $232,484 |
| TivicayDolutegravir Sodium | 78 | $231,851 |
| DovatoDolutegravir Sodium/Lamivudine | 68 | $191,598 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 47 | $180,079 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 44 | $175,446 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 37 | $173,507 |
| RukobiaFostemsavir Tromethamine | 20 | $166,387 |
| DescovyEmtricitabine/Tenofov Alafenam | 36 | $73,166 |
| PrezcobixDarunavir/Cobicistat | 19 | $39,771 |
| PifeltroDoravirine | 15 | $24,551 |
| EdurantRilpivirine Hcl | 13 | $21,128 |
| Spiriva HandihalerTiotropium Bromide | 19 | $9,725 |
| JardianceEmpagliflozin | 15 | $7,859 |
| Lamivudine | 31 | $5,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $58,416 | $3,185,896828 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Rukobia | $23,635 | $769,915213 claims |
| Janssen Products, LPSymtuza | $4,492 | $173,50737 claims |
| MerckPifeltro | $292 | $24,55115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Houston
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
- Edward SeptimusHouston$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.